

Viral lung infections: from common cold to severe acute respiratory syndrome.

Sandhya Josheu*

Department of Medicine and Infectious Disease and International Health, University of Virginia, USA

Abstract

Lung infections are a significant cause of morbidity and mortality worldwide. Viral infections of the lungs range from mild common colds to severe acute respiratory syndrome (SARS), a potentially fatal condition. In this article, we will discuss viral lung infections, their symptoms, and treatments. The common cold is the most common viral infection of the respiratory tract. It is caused by several viruses, including rhinoviruses, coronaviruses, and respiratory syncytial virus (RSV).

Keywords: Lung infections, Respiratory syndrome, Rhinoviruses, Respiratory syncytial virus.

Introduction

Symptoms of the common cold include a runny nose, cough, sore throat, and fever. Treatment is supportive and includes rest, fluids, and over-the-counter medications to alleviate symptoms. Influenza, or the flu, is another viral infection of the lungs. It is caused by the influenza virus and is highly contagious. Symptoms of the flu include fever, cough, sore throat, muscle aches, and fatigue. Treatment for the flu includes antiviral medications, rest, and fluids. Vaccination is the best way to prevent the flu [1].

Pneumonia is a more serious lung infection that can be caused by viruses such as influenza, respiratory syncytial virus, and adenovirus. Symptoms of pneumonia include fever, cough, chest pain, and shortness of breath. Treatment for pneumonia includes antibiotics for bacterial pneumonia and antiviral medications for viral pneumonia. Severe Acute Respiratory Syndrome (SARS) is a rare but potentially fatal viral infection of the lungs. It is caused by the SARS coronavirus and was first identified in 2003. Symptoms of SARS include fever, cough, shortness of breath, and pneumonia. Treatment for SARS is supportive and includes antiviral medications, oxygen therapy, and mechanical ventilation [2].

Middle East Respiratory Syndrome (MERS) is another rare but potentially fatal viral infection of the lungs. It is caused by the MERS coronavirus and was first identified in Saudi Arabia in 2012. Symptoms of MERS include fever, cough, shortness of breath, and pneumonia. Treatment for MERS is supportive and includes antiviral medications, oxygen therapy, and mechanical ventilation. COVID-19, caused by the SARS-CoV-2 virus, is a respiratory illness that has become a global pandemic since its emergence in 2019. Symptoms of COVID-19 include fever, cough and shortness of breath,

fatigue, and body aches. While many people with COVID-19 experience mild or no symptoms, others may develop severe disease, including pneumonia and acute respiratory distress syndrome (ARDS). Treatment for COVID-19 is supportive and includes antiviral medications, oxygen therapy, and mechanical ventilation [3].

Prevention of viral lung infections involves good hygiene practices, such as washing hands frequently, covering coughs and sneezes, and avoiding close contact with people who are sick. Vaccines are available for some viral infections, such as the flu, and have been shown to reduce the risk of infection and severe disease [4]. The treatment of viral lung infections depends on the specific virus causing the infection, the severity of the infection, and the individual patient's medical history and overall health. In general, treatment of viral lung infections focuses on relieving symptoms and supporting the immune system to fight off the infection. For common viral lung infections such as the common cold and flu, over-the-counter medications such as acetaminophen or ibuprofen can be used to relieve fever, headache, and muscle aches. Decongestants and antihistamines can be used to relieve nasal congestion, cough, and sneezing. Rest, hydration, and a healthy diet are also important in helping the body fight off the infection. For more severe viral lung infections such as SARS or COVID-19, antiviral medications may be used in addition to supportive care. Antiviral drugs such as Remdesivir have been shown to be effective in reducing the severity and duration of COVID-19. Corticosteroids may also be used to reduce inflammation in the lungs [5].

Conclusion

It's important to note that not all viral lung infections require medication. For mild infections, rest and self-care may be

*Correspondence to: Sandhya Josheu, Department of Medicine and Infectious Disease and International Health, University of Virginia, USA, E mail: sandhyajoy@virginia.edu

Received: 22-Mar-2023, Manuscript No. AAIJRM-23-95122; Editor assigned: 24-Mar-2023, PreQC No. AAIJRM-23-95122(PQ); Reviewed: 07-Apr-2023, QC No. AAIJRM-23-95122; Revised: 11-Apr-2023, Manuscript No. AAIJRM-23-95122(R); Published: 18-Apr-2023, DOI: 10.35841/aijrm-8.2.140

all that is needed. However, if symptoms worsen or persist, it's important to seek medical attention to determine the best course of treatment. In conclusion, viral lung infections range from mild common colds to severe and potentially fatal illnesses such as SARS, MERS, and COVID-19. Symptoms of viral lung infections include fever, cough, and shortness of breath, and treatment is supportive and may include antiviral medications, oxygen therapy, and mechanical ventilation. Prevention of viral lung infections involves good hygiene practices and vaccination.

References

1. D'Anna SE, Maniscalco M, Cappello F, et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. *Ann Med.* 2021;53(1):135-50.
2. Groves HT, Cuthbertson L, James P, et al. Respiratory disease following viral lung infection alters the murine gut microbiota. *Front Immunol.* 2018;9:182.
3. Meyerholz DK, Beck AP. Histopathology evaluation and scoring of viral lung infection. *Methods Mol Biol.* 2020:205-20.
4. Roberts H, Lim WS. Viral lung infections and the potential for a human pandemic. *Med.* 2008;36(6):291-4.
5. Wang R, Xiao H, Guo R, et al. The role of C5a in acute lung injury induced by highly pathogenic viral infections. *Emer Micro Infect.* 2015;4(1):1-7.